GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
These results indicate that the increased amount of non-12-OH FXR-antagonistic BAs consequent to the decrease in CYP8B1 expression after T3 treatment potentiates GLP-1 production by deactivating the intestinal FXR, thereby improving glucose homeostasis via the augmentation of insulin secretion
Interestingly, the same cells grown in 3D conditions were completely resistant to lipid peroxidation, in perfect agreement with the lack of sensitivity to cell death induced by RSL3 (Figs
Non-oral methods, such as IUDs, implants, the patch, the ring, and the shot, are the most reliable choices because theyre not affected by changes in digestion or absorption
F.ChoukemS